VGR R01
Alternative Names: VGR-R01Latest Information Update: 25 Jan 2023
At a glance
- Originator Shanghai Vitalgen BioPharma
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action CYP4V2 protein replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Bietti crystalline dystrophy
Most Recent Events
- 23 Jan 2023 Shanghai Vitalgen BioPharma plans a phase I trial for Retinal disorder in 2023 in China (Ophthalmic) (NCT05694598)
- 11 Jul 2022 Vitalgen files an IND application with the National Medical Products Administration (NMPA) in China for Bietti Crystalline Dystrophy (Vitalgen pipeline, July 2022).
- 08 Jul 2022 Clinical trial in Bietti crystalline dystrophy in China (Ophthalmic) (Vitalgen pipeline, July 2022)